The company said fiscal 2024 net sales for Q4 rose 2% to $306.1 million, with organic revenue up 1%. Full-year net sales increased 2% to $1.2 billion, and organic revenue rose 1%.

1. 01

   The company said fiscal 2024 net sales for Q4 rose 2% to $306.1 million, with organic revenue up 1%. Full-year net sales increased 2% to $1.2 billion, and organic revenue rose 1%.

2. 02

   Bio-Techne said GAAP diluted EPS for Q4 was $0.25 (versus $0.47 a year earlier), and adjusted EPS was $0.49 (versus $0.55 a year earlier). Full-year GAAP EPS was $1.05 (versus $1.76 a year earlier), and full-year adjusted EPS was $1.77 (versus $1.99 a year earlier).

3. 03

   The company said GAAP operating income for Q4 fell 52% to $45.8 million, with a GAAP operating margin of 15.0%. It cited impairment of assets held-for-sale, restructuring and CEO transition costs, certain litigation charges, and the acquisition of Lunaphore as factors affecting its GAAP operating margin.

4. 04

   Bio-Techne said cash flow from operations for fiscal 2024 rose 18% from the prior year to $299.0 million. Over the same full-year period, it paid $50,419 thousand in dividends and repurchased $80,042 thousand of its shares.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.